Chester County News and Community Website
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced its 2024 financial results, highlighting progress in its PBFT02 gene therapy program for frontotemporal dementia (FTD) associated with GRN mutations (FTD-GRN) …
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced its participation in two upcoming investor conferences, where management will share updates on the company’s progress and engage with stakeholders.
Passage Bio to Present at Two Major Investor Conferences Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which evaluates PBFT02 as a potential treatment for frontotemporal dementia …
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, highlighting substantial progress in its PBFT02 gene therapy program for frontotemporal dementia …
Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that Will Chou, M.D., the president and chief executive officer of the company, will be presenting at the prestigious Guggenheim Securities …
Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference! Read More PHILADELPHIA, PA — Will Chou, M.D., the president and CEO of Passage Bio (NASDAQ: PASG), is set to present at Chardan’s 8th Annual Genetic Medicines Conference on October 1, 2024.
Passage Bio’s CEO to Present at Prestigious Genetic Medicines Conference Read More PHILADELPHIA, PA — Passage Bio, Inc. has unveiled promising interim data from its ongoing global Phase 1/2 upliFT-D clinical trial at the 14th International Conference on Frontotemporal Dementias (ISFTD2024). The study …
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has announced the appointment of Tom Kassberg to its Board of Directors, along with his role on the Audit Committee, marking a significant …
Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision Read More PHILADELPHIA, PA — Passage Bio, Inc. has announced that its President and CEO, Will Chou, M.D., will present at the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The presentation …
Passage Bio CEO to Present at H.C. Wainwright Global Investment Conference Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) released its financial results for the second quarter ended June 30, 2024, along with significant business highlights.
Passage Bio Reports Q2 2024 Financial Results and Business Updates Read More